Northland initiates ARS Pharmaceuticals coverage with an outperform rating

ru.investing.com (Russian)

Northland initiated coverage of ARS Pharmaceuticals with an "Outperform" rating and a $25 price target. The firm highlighted ARS's needle-free nasal epinephrine product, neffy, projecting over $1 billion in U.S. peak sales due to expected market access improvements. Recent positive developments include exceeding Q4 earnings and revenue expectations and FDA label updates for neffy, with other analysts also maintaining positive ratings.


With a significance score of 1.3, this news ranks in the top 44% of today's 31597 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Northland initiates ARS Pharmaceuticals coverage with an outperform rating | News Minimalist